Key result
Dexmedetomidine as an adjuvant to bupivacaine significantly prolonged the duration of sensory block (876 vs 659.6 minutes) and motor block compared to dexamethasone.
Why the study?
Various adjuvants are used with local anesthetics to enhance block quality and duration, prompting an evaluation comparing dexmedetomidine and dexamethasone for onset, sensorimotor block duration, hemodynamics, and postoperative analgesia.
Does dexmedetomidine compared to dexamethasone improve the onset and duration of sensorimotor block in patients undergoing upper limb procedures under supraclavicular brachial plexus block?
RCT (n=60)
Computer generated number
No
Does dexmedetomidine compared to dexamethasone improve the onset and duration of sensorimotor block in patients undergoing upper limb procedures under supraclavicular brachial plexus block?
Absolute Event Rate: 876% vs 659.6%
p-value: p=<0.001
Dexmedetomidine is superior to dexamethasone as an adjuvant to bupivacaine for rapid onset and prolonged duration of sensorimotor block in supraclavicular brachial plexus block.
May support dexmedetomidine or dexamethasone as adjuvants in brachial plexus block; leaves open need for larger RCTs before practice change.
Objective: Brachial plexus block is one of the commonly used anesthetic technique for upper limb procedures in orthopedics. A number of drugs have been used as adjuvants to local anesthetic agents, to prolong the duration and enhance the quality of the block. Some of these are clonidine, dexmedetomidine, ketamine, dexamethasone and magnesium sulfate. We conducted this study to evaluate dexmedetomidine and dexamethasone with respect to the onset and duration of sensorimotor block. Their effects on hemodynamic parameters as well as duration of analgesia after surgery were also recorded. Study Design: Prospective Randomized controlled design. Settings: Anesthesia, ICU and pain management department of Services Hospital/SIMS, Lahore Pakistan. Duration: From 15th September 2019 till 15th March 2020. Methodology: Sixty patients fulfilling the inclusion criteria were enrolled in the study after taking informed written consent for upper limb procedures under supraclavicular brachial plexus block. These patients were divided into two groups BD and BG with 30 patients in each group. Patients in Group BD received 32ml of 0.375% bupivacaine (30 ml) with 100microgram of dexmedetomidine(2ml). Group BG patients received 32ml of 0.375% bupivacaine(30ml) with 8mg of dexamethasone (2ml). The onset and duration of sensory and motor block, time to request for first rescue analgesic and hemodynamic changes in both groups of patients were recorded. Results: The results of our study revealed that the patients in group BD had earlier onset and longer duration of sensory and motor block with minimal hemodynamic changes. Conclusion: Dexmedetomidine is superior to dexamethasone as an adjuvant, in terms of rapid onset and prolonged duration of sensorimotor block and postoperative analgesia after supraclavicular block, with minimal hemodynamic changes.
No takes yet. Share an insight, caveat, or question.
Khaleeq et al. (2020) conducted an RCT in Upper limb orthopedic procedures requiring supraclavicular brachial plexus block (n=60). Dexmedetomidine vs. Dexamethasone 8 mg was evaluated on Duration of sensory block (minutes) (p=<0.001). Dexmedetomidine as an adjuvant to bupivacaine significantly prolonged the duration of sensory block (876 vs 659.6 minutes) and motor block compared to dexamethasone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: